Compare · ABT vs GNLX
ABT vs GNLX
Side-by-side comparison of Abbott Laboratories (ABT) and Genelux Corporation (GNLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and GNLX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $155.32B, about 1211.1x GNLX ($128.2M).
- Over the past year, ABT is down 33.5% and GNLX is up 10.0% - GNLX leads by 43.5 points.
- ABT has been more active in the news (6 items in the past 4 weeks vs 2 for GNLX).
- ABT has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- Abbott Laboratories
- Genelux Corporation
- Price
- $89.78+0.77%
- $2.87-0.52%
- Market cap
- $155.32B
- $128.2M
- 1M return
- +6.38%
- -2.38%
- 1Y return
- -33.54%
- +9.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 6
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest GNLX
- Head of Regulatory Smalling Ralph sold $563 worth of shares (192 units at $2.93), decreasing direct ownership by 0.28% to 67,611 units (SEC Form 4)
- Director Thomas John sold $29,801 worth of shares (10,000 units at $2.98) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 472,784 units (SEC Form 4)
- Chief Technical Officer Cappello Joseph sold $1,799 worth of shares (605 units at $2.97), decreasing direct ownership by 0.39% to 154,549 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $1,798 worth of shares (605 units at $2.97), decreasing direct ownership by 0.40% to 149,706 units (SEC Form 4)
- Head of Regulatory Smalling Ralph sold $804 worth of shares (270 units at $2.98), decreasing direct ownership by 0.40% to 67,803 units (SEC Form 4)
- President and CEO Zindrick Thomas sold $8,226 worth of shares (2,798 units at $2.94), decreasing direct ownership by 0.52% to 532,051 units (SEC Form 4)
- Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Genelux Corporation
- SEC Form DEFA14A filed by Genelux Corporation
- SEC Form DEF 14A filed by Genelux Corporation